Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash & Equivalents (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Cash & Equivalents for 16 consecutive years, with $20.9 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 50.14% year-over-year to $20.9 million; the TTM value through Dec 2025 reached $20.9 million, down 50.14%, while the annual FY2025 figure was $20.9 million, 50.14% down from the prior year.
  • Cash & Equivalents hit $20.9 million in Q4 2025 for Sangamo Therapeutics, down from $29.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $178.9 million in Q4 2021 and bottomed at $20.9 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $80.3 million, with a median of $61.7 million recorded in 2023.
  • On a YoY basis, Cash & Equivalents climbed as much as 43.41% in 2021 and fell as far as 63.66% in 2021.
  • Sangamo Therapeutics' Cash & Equivalents stood at $178.9 million in 2021, then plummeted by 43.85% to $100.4 million in 2022, then tumbled by 55.0% to $45.2 million in 2023, then fell by 7.27% to $41.9 million in 2024, then tumbled by 50.14% to $20.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $20.9 million, $29.6 million, and $38.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.